Immune escape mechanisms of intraocular tumors

Progress in Retinal and Eye Research

Volumn 28, Issue 5, 2009, Pages 329-347

  Niederkorn, Jerry Y ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Anterior chamber; Immune escape; Immune privilege; Immune surveillance; Metastasis; Natural killer cells; Uveal melanoma

Indexed keywords

CYTOKINE; FAS LIGAND; INDOLEAMINE 2,3 DIOXYGENASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ADAPTIVE IMMUNITY; ALLOGRAFT; ANTIGEN ANTIBODY REACTION; ANTIGEN EXPRESSION; APOPTOSIS; AQUEOUS HUMOR FLOW; BONE MARROW CELL; CANCER CELL; CANCER GENETICS; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CELL ACTIVITY; CELL CYCLE ARREST; CELL PROLIFERATION; CYTOGENETICS; CYTOLOGY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; EYE INFLAMMATION; EYE PROTECTION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; INNATE IMMUNITY; INTRAOCULAR TUMOR; LIVER METASTASIS; LUNG CANCER; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; NONHUMAN; ONCOGENE; PATHOLOGICAL ANATOMY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SUPPRESSOR CELL; SURVIVAL TIME; TARGET CELL DESTRUCTION; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR IMMUNOLOGY; TUMOR REJECTION; TUMOR XENOGRAFT; UVEA MELANOMA;

ANIMALS; EYE NEOPLASMS; HUMANS; IMMUNE SYSTEM; MELANOMA; TUMOR ESCAPE; UVEAL NEOPLASMS;

EID: 67651183589     PISSN: 13509462     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2009.06.002     Document Type: Review

References (261)

1. Abi-Hanna D., Wakefield D., et al. HLA antigens in ocular tissues. I. In vivo expression in human eyes. Transplantation 45 (1988) 610-613
2. Agata Y., Kawasaki A., et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8 (1996) 765-772
3. Albert D.M. The ocular melanoma story. LIII Edward Jackson Memorial Lecture: Part II. Am. J. Ophthalmol. 123 (1997) 729-741
4. Alexander A.M., Crawford M., et al. Indoleamine 2,3-dioxygenase expression in transplanted NOD islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes. Diabetes 51 (2002) 356-365
5. Algarra I., Cabrera T., et al. The HLA crossroad in tumor immunology. Hum. Immunol. 61 (2000) 65-73
6. Alizadeh H., Howard K., et al. Reduction of liver metastasis of intraocular melanoma by interferon-beta gene transfer. Invest. Ophthalmol. Vis. Sci. 44 (2003) 3042-3051
7. Anand R., Ma D., et al. Characterization of intraocular tumors arising in transgenic mice. Invest. Ophthalmol. Vis. Sci. 35 (1994) 3533-3539
8. Anastassiou G., Coupland S.E., et al. Expression of Fas and Fas ligand in uveal melanoma: biological implication and prognostic value. J. Pathol. 194 (2001) 466-472
9. Apte R.S., Mayhew E., et al. Local inhibition of natural killer cell activity promotes the progressive growth of intraocular tumors. Invest. Ophthalmol. Vis. Sci. 38 (1997) 1277-1282
10. Apte R.S., and Niederkorn J.Y. Isolation and characterization of a unique natural killer cell inhibitory factor present in the anterior chamber of the eye. J. Immunol. 156 (1996) 2667-2673
11. Apte R.S., Sinha D., et al. Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J. Immunol. 160 (1998) 5693-5696
12. Ashton N. Primary tumors of the iris. Br. J. Ophthalmol. 48 (1964) 650-668
13. Astigiano S., Morandi B., et al. Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer. Neoplasia 7 (2005) 390-396
14. Augsburger J.J., Mullen D., et al. Planned combined I-125 plaque irradiation and indirect ophthalmoscope laser therapy for choroidal malignant melanoma. Ophthal. Surg. 24 (1993) 76-81
15. Balkwill F., Charles K.A., et al. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7 (2005) 211-217
16. Balkwill F., and Mantovani A. Inflammation and cancer: back to virchow?. Lancet 357 (2001) 539-545
17. Baniyash M. TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat. Rev. Immunol. 4 (2004) 675-687
18. Beatty G.L., and Paterson Y. IFN-gamma can promote tumor evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumor antigen. J. Immunol. 165 (2000) 5502-5508
19. Beutelspacher S.C., Pillai R., et al. Function of indoleamine 2,3-dioxygenase in corneal allograft rejection and prolongation of allograft survival by over-expression. Eur. J. Immunol. 36 (2006) 690-700
20. Bill A. Ocular circulation. In: Moses R.A. (Ed). Adler's Physiology of the Eye (1970), C.V. Mosby Co., St. Louis 278-296
21. Billingham R.E., and Boswell T. Studies on the problem of corneal homografts. Proc. R. Soc. Lond. B Biol. Sci. 141 (1953) 392-406
22. Billingham R.E., Krohn P.L., et al. Effect of cortisone on survival of skin homografts in rabbits. Br. Med. J. 1 (1951) 1157-1163
23. Birkeland S.A., Storm H.H., et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int. J. Cancer 60 (1995) 183-189
24. Blank C., Brown I., et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8 + T cells. Cancer Res. 64 (2004) 1140-1145
25. Blom D.J., Goslings W.R., et al. Lack of effect of different cytokines on expression of membrane-bound regulators of complement activity on human uveal melanoma cells. J. Interferon Cytokine Res. 17 (1997) 695-700
26. Blom D.J., Luyten G.P., et al. Human leukocyte antigen class I expression. Marker of poor prognosis in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 38 (1997) 1865-1872
27. Blom D.J., Mooy C.M., et al. Inverse correlation between expression of HLA-B and c-myc in uveal melanoma. J. Pathol. 181 (1997) 75-79
28. Blom D.J., Schurmans L.R., et al. HLA expression in a primary uveal melanoma, its cell line, and four of its metastases. Br. J. Ophthalmol. 81 (1997) 989-993
29. Bodaghi B., Goureau O., et al. Role of IFN-gamma-induced indoleamine 2,3 dioxygenase and inducible nitric oxide synthase in the replication of human cytomegalovirus in retinal pigment epithelial cells. J. Immunol. 162 (1999) 957-964
30. Boonman Z.F., Schurmans L.R., et al. Macrophages are vital in spontaneous intraocular tumor eradication. Invest. Ophthalmol. Vis. Sci. 47 (2006) 2959-2965
31. Bora N.S., Gobleman C.L., et al. Differential expression of the complement regulatory proteins in the human eye. Invest. Ophthalmol. Vis. Sci. 34 (1993) 3579-3584
32. Bosch J.J., Thompson J.A., et al. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells. Cancer Res. 67 (2007) 4499-4506
33. Brandacher G., Perathoner A., et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin. Cancer Res. 12 (2006) 1144-1151
34. Brocker E.B., Suter L., et al. Phenotypic dynamics of tumor progression in human malignant melanoma. Int. J. Cancer 36 (1985) 29-35
35. Bronte V., Serafini P., et al. l-Arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol. 24 (2003) 302-306
36. Bronte V., and Zanovello P. Regulation of immune responses by l-arginine metabolism. Nat. Rev. Immunol. 5 (2005) 641-654
37. Burnet M. Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications. Br. Med. J. 1 (1957) 841-847
38. Callaway M.P., and Briggs J.C. The incidence of late recurrence (greater than 10 years); an analysis of 536 consecutive cases of cutaneous melanoma. Br. J. Plast. Surg. 42 (1989) 46-49
39. Camelo S., Kezic J., et al. Antigen from the anterior chamber of the eye travels in a soluble form to secondary lymphoid organs via lymphatic and vascular routes. Invest. Ophthalmol. Vis. Sci. 47 (2006) 1039-1046
40. Camelo S., Shanley A., et al. The distribution of antigen in lymphoid tissues following its injection into the anterior chamber of the rat eye. J. Immunol. 172 (2004) 5388-5395
41. Carreno B.M., and Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Ann. Rev. Immunol. 20 (2002) 29-53
42. Char D.H. Metastatic choroidal melanoma. Am. J. Ophthalmol. 86 (1978) 76-80
43. Chen P.W., and Ksander B.R. Influence of immune surveillance and immune privilege on formation of intraocular tumors. Chem. Immunol. Allergy 92 (2007) 276-289
44. Chen P.W., Mellon J.K., et al. Uveal melanoma expression of indoleamine 2,3-deoxygenase: establishment of an immune privileged environment by tryptophan depletion. Exp. Eye Res. 85 (2007) 617-625
45. Chen P.W., Murray T.G., et al. Expression of MAGE genes in ocular melanoma cell lines. J. Immunother. 20 (1997) 265-275
46. Coley W.B. II. Contribution to the knowledge of sarcoma. Ann. Surg. 14 (1891) 199-220
47. Coley W.B. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am. J. Med. Sci. 105 (1893) 487-511
48. COMS. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS Report No. 15. Arch. Ophthalmol. 119 (2001) 670-676
49. Cousins S.W., McCabe M.M., et al. Identification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor. Invest. Ophthalmol. Vis. Sci. 32 (1991) 2201-2211
50. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860-867
51. D'Orazio T.J., DeMarco B.M., et al. Effect of aqueous humor on apoptosis of inflammatory cell types. Invest. Ophthalmol. Vis. Sci. 40 (1999) 1418-1426
52. D'Orazio T.J., and Niederkorn J.Y. The nature of antigen in the eye has a profound effect on the cytokine milieu and resultant immune response. Eur. J. Immunol. 28 (1998) 1544-1553
53. D'Orazio T.J., and Niederkorn J.Y. A novel role for TGF-beta and IL-10 in the induction of immune privilege. J. Immunol. 160 (1998) 2089-2098
54. Dace D.S., Chen P.W., et al. Ocular immune privilege is circumvented by CD4 + T cells, leading to the rejection of intraocular tumors in an IFN-{gamma}-dependent manner. J. Leukoc. Biol. 81 (2007) 421-429
55. Dace D.S., Chen P.W., et al. CD8 + T cells circumvent immune privilege in the eye and mediate intraocular tumor rejection by a TNF-a-dependent mechanism. J. Immunol 178 (2007) 6115-6122
56. Dace D.S., Chen P.W., et al. CD4 + T-cell-dependent tumour rejection in an immune-privileged environment requires macrophages. Immunology 123 (2008) 367-377
57. Dannenberg A.J., and Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 4 (2003) 431-436
58. Daubener W., and MacKenzie C.R. IFN-gamma activated indoleamine 2,3-dioxygenase activity in human cells is an antiparasitic and an antibacterial effector mechanism. Adv. Exp. Med. Biol. 467 (1999) 517-524
59. de la Cruz Jr. P.O., Specht C.S., et al. Lymphocytic infiltration in uveal malignant melanoma. Cancer 65 (1990) 112-115
60. de Waard-Siebinga I., Hilders C.G., et al. HLA expression and tumor-infiltrating immune cells in uveal melanoma. Graefes Arch. Clin. Exp. Ophthalmol. 234 (1996) 34-42
61. Della Chiesa M., Carlomagno S., et al. The tryptophan catabolite l-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. Blood 108 (2006) 4118-4125
62. Demicheli R., Abbattista A., et al. Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res. Treat 41 (1996) 177-185
63. Ding H., Wu X., et al. PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis. Clin. Immunol. 115 (2005) 184-191
64. Dithmar S., Rusciano D., et al. Neoadjuvant interferon alfa-2b treatment in a murine model for metastatic ocular melanoma: a preliminary study. Arch. Ophthalmol. 118 (2000) 1085-1089
65. Dithmar S.A., Rusciano D.A., et al. Depletion of NK cell activity results in growth of hepatic micrometastases in a murine ocular melanoma model. Curr. Eye Res. 19 (1999) 426-431
66. Dong H., Strome S.E., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8 (2002) 793-800
67. Dong H., Zhu G., et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 5 (1999) 1365-1369
68. Dunn G.P., Bruce A.T., et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3 (2002) 991-998
69. Dunn G.P., Koebel C.M., et al. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6 (2006) 836-848
70. Dunn G.P., Old L.J., et al. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21 (2004) 137-148
71. Dunn G.P., Old L.J., et al. The three Es of cancer immunoediting. Ann. Rev. Immunol. 22 (2004) 329-360
72. Durie F.H., Campbell A.M., et al. Analysis of lymphocytic infiltration in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 31 (1990) 2106-2110
73. Egan R.M., Yorkey C., et al. Peptide-specific T cell clonal expansion in vivo following immunization in the eye, an immune-privileged site. J. Immunol. 157 (1996) 2262-2271
74. Ehrlich P. Ueber den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneeskd 5 (1909) 273-290
75. Ericsson C., Seregard S., et al. Association of HLA class I and class II antigen expression and mortality in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 42 (2001) 2153-2156
76. Esser P., Grisanti S., et al. TGF-beta in uveal melanoma. Microsc. Res. Tech. 52 (2001) 396-400
77. Filer R.S., Song J.C., et al. Cytokines in uveal melanoma (Original title: uveal melanoma cytokines). Klin. Monatsbl. Augenheilkd 202 (1993) 174-179
78. Freeman G.J., Long A.J., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192 (2000) 1027-1034
79. Frumento G., Rotondo R., et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med. 196 (2002) 459-468
80. Gabrilovich D.I., and Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9 (2009) 162-174
81. Gombos D.S., and Mieler W.F. Therapy of uveal melanoma: methods and risk factors associated with treatment. In: Albert D.M., and Polans A. (Eds). Ocular Oncology (2003), Marcel Dekker, Inc., New York 321-352
82. Goslings W.R., Blom D.J., et al. Membrane-bound regulators of complement activation in uveal melanomas. CD46, CD55, and CD59 in uveal melanomas. Invest. Ophthalmol. Vis. Sci. 37 (1996) 1884-1891
83. Goslings W.R., Prodeus A.P., et al. A small molecular weight factor in aqueous humor acts on C1q to prevent antibody-dependent complement activation. Invest. Ophthalmol. Vis. Sci. 39 (1998) 989-995
84. Greene H.S. A spontaneous melanoma in the hamster with a propensity for amelanotic alteration and sarcomatous transformation during transplantation. Cancer Res. 18 (1958) 422-425
85. Griffith T.S., Brunner T., et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270 (1995) 1189-1192
86. Hainz U., Jurgens B., et al. The role of indoleamine 2,3-dioxygenase in transplantation. Transpl. Int. 20 (2007) 118-127
87. Hallermalm K., De Geer A., et al. Autocrine secretion of fas ligand shields tumor cells from fas-mediated killing by cytotoxic lymphocytes. Cancer Res. 64 (2004) 6775-6782
88. Hallermalm K., Seki K., et al. Modulation of the tumor cell phenotype by IFN-gamma results in resistance of uveal melanoma cells to granule-mediated lysis by cytotoxic lymphocytes. J. Immunol. 180 (2008) 3766-3774
89. Hargrave S.L., Mayhew E., et al. Are corneal cells susceptible to antibody-mediated killing in corneal allograft rejection?. Transpl. Immunol. 11 (2003) 79-89
90. He Y.F., Wang X.H., et al. Sustained low-level expression of interferon-gamma promotes tumor development: potential insights in tumor prevention and tumor immunotherapy. Cancer Immunol. Immunother. 54 (2005) 891-897
91. He Y.G., Mayhew E., et al. Expression and possible function of IL-2 and IL-15 receptors on human uveal melanoma cells. Invest. Ophthalmol. Vis. Sci. 45 (2004) 4240-4246
92. Hegde S., Mellon J.K., et al. Effect of alloantibodies on corneal allograft survival. Invest. Ophthalmol. Vis. Sci. 43 (2002) 1012-1018
93. Helbig H., Gurley R.C., et al. Dual effect of ciliary body cells on T lymphocyte proliferation. Eur. J. Immunol. 20 (1990) 2457-2463
94. Herrlinger U., Hebart H., et al. Relapse of primary CNS lymphoma after more than 10 years in complete remission. J. Neurol. 252 (2005) 1409-1410
95. Hicklin D.J., Marincola F.M., et al. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol. Med. Today 5 (1999) 178-186
96. Holmes C.H., Simpson K.L., et al. Complement regulatory proteins at the feto-maternal interface during human placental development: distribution of CD59 by comparison with membrane cofactor protein (CD46) and decay accelerating factor (CD55). Eur. J. Immunol. 22 (1992) 1579-1585
97. Holmes C.H., Simpson K.L., et al. Preferential expression of the complement regulatory protein decay accelerating factor at the fetomaternal interface during human pregnancy. J. Immunol. 144 (1990) 3099-3105
98. Hooper P., Bora N.S., et al. Inhibition of lymphocyte proliferation by resident ocular cells. Curr. Eye Res. 10 (1991) 363-372
99. Hori J., Wang M., et al. B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts. J. Immunol. 177 (2006) 5928-5935
100. Ino K., Yoshida N., et al. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br. J. Cancer 95 (2006) 1555-1561
101. Irving B.A., and Weiss A. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 64 (1991) 891-901
102. Ishio T., Goto S., et al. Immunoactivative role of indoleamine 2,3-dioxygenase in human hepatocellular carcinoma. J. Gastroenterol. Hepatol. 19 (2004) 319-326
103. Ishitani A., and Geraghty D.E. Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens. Proc. Natl. Acad. Sci. USA 89 (1992) 3947-3951
104. Jager M.J., Hurks H.M., et al. HLA expression in uveal melanoma: there is no rule without some exception. Hum. Immunol. 63 (2002) 444-451
105. Jager M.J., Hurks H.M.H., et al. HLA expressin in uveal melanoma: there is no rule without some exception. Hum. Immunol. 63 (2002) 444-451
106. Jampel H.D., Roche N., et al. Transforming growth factor-beta in human aqueous humor. Curr. Eye Res. 9 (1990) 963-969
107. Jensen O.A., and Anderson S.R. Spontaneous regression of malignant melanoma of the choroid. Acta Ophthalmol. (Copenh.) 52 (1974) 173-182
108. Joly E., Mucke L., et al. Viral persistence in neurons explained by lack of major histocompatibility class I expression. Science 253 (1991) 1283-1285
109. Kan-Mitchell J., Liggett P.E., et al. Lymphocytes cytotoxic to uveal and skin melanoma cells from peripheral blood of ocular melanoma patients. Cancer Immunol. Immunother. 33 (1991) 333-340
110. Kaplan D.H., Shankaran V., et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA 95 (1998) 7556-7561
111. Kaplan H.J., and Stevens T.R. A reconsideration of immunological privilege within the anterior chamber of the eye. Transplantation 19 (1975) 203-209
112. Kaplan H.J., and Streilein J.W. Immune response to immunization via the anterior chamber of the eye. I.F. lymphocyte-induced immune deviation. J. Immunol. 118 (1977) 809-814
113. Kaplan H.J., and Streilein J.W. Immune response to immunization via the anterior chamber of the eye. II. An analysis of F1 lymphocyte-induced immune deviation. J. Immunol. 120 (1978) 689-693
114. Kaplan H.J., Streilein J.W., et al. Transplantation immunology of the anterior chamber of the eye. II. Immune response to allogeneic cells. J. Immunol. 115 (1975) 805-810
115. Kath R., Hayungs J., et al. Prognosis and treatment of disseminated uveal melanoma [see comments]. Cancer 72 (1993) 2219-2223
116. Kelly S.A., Gschmeissner S., et al. Enhancement of metastatic potential by gamma-interferon. Cancer Res. 51 (1991) 4020-4027
117. Khodadoust A.A., Roozitalab H.M., et al. Spontaneous regression of retinoblastoma. Surv. Ophthalmol. 21 (1977) 467-478
118. Khong H.T., and Restifo N.P. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol. 3 (2002) 999-1005
119. Klein G. Tumor antigens. Ann. Rev. Microbiol. 20 (1966) 223-252
120. Knisely T.L., Bleicher P.A., et al. Production of latent transforming growth factor-beta and other inhibitory factors by cultured murine iris and ciliary body cells. Curr. Eye Res. 10 (1991) 761-771
121. Knisely T.L., Luckenbach M.W., et al. Destructive and nondestructive patterns of immune rejection of syngeneic intraocular tumors. J. Immunol. 138 (1987) 4515-4523
122. Knisely T.L., and Niederkorn J.Y. Emergence of a dominant cytotoxic T lymphocyte antitumor effector from tumor-infiltrating cells in the anterior chamber of the eye. Cancer Immunol. Immunother. 30 (1990) 323-330
123. Kobayashi N. Malignant neoplasms in registered cases of primary immunodeficiency syndrome. Jpn. J. Clin. Oncol. 15 Suppl. 1 (1985) 307-312
124. Kovats S., Main E.K., et al. A class I antigen, HLA-G, expressed in human trophoblasts. Science 248 (1990) 220-223
125. Ksander B.R., Geer D.C., et al. Uveal melanomas contain antigenically specific and non-specific infiltrating lymphocytes. Curr. Eye Res. 17 (1998) 165-173
126. Ksander B.R., Rubsamen P.E., et al. Studies of tumor-infiltrating lymphocytes from a human choroidal melanoma. Invest. Ophthalmol. Vis. Sci. 32 (1991) 3198-3208
127. Kusmartsev S., Nefedova Y., et al. Antigen-specific inhibition of CD8 + T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol. 172 (2004) 989-999
128. Lai P., Rabinowich H., et al. Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin. Cancer Res. 2 (1996) 161-173
129. Lampson L.A., and Fisher C.A. Weak HLA and beta 2-microglobulin expression of neuronal cell lines can be modulated by interferon. Proc. Natl. Acad. Sci. USA 81 (1984) 6476-6480
130. Lass J.H., Walter E.I., et al. Expression of two molecular forms of the complement decay-accelerating factor in the eye and lacrimal gland. Invest. Ophthalmol. Vis. Sci. 31 (1990) 1136-1148
131. Latchman Y., Wood C.R., et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2 (2001) 261-268
132. Le Discorde M., Moreau P., et al. Expression of HLA-G in human cornea, an immune-privileged tissue. Hum. Immunol. 64 (2003) 1039-1044
133. Le Poole I.C., Riker A.I., et al. Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells. Am. J. Pathol. 160 (2002) 521-528
134. LeBouteiller P. HLA class I chromosomal region, genes, and products: facts and questions. Crit. Rev. Immunol. 14 (1994) 89-129
135. Lee H.O., Herndon J.M., et al. TRAIL: a mechanism of tumor surveillance in an immune privileged site. J. Immunol. 169 (2002) 4739-4744
136. Lee N., Llano M., et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc. Natl. Acad. Sci. USA 95 (1998) 5199-5204
137. Li X., Taylor S., et al. The induction of splenic suppressor T cells through an immune-privileged site requires an intact sympathetic nervous system. J. Neuroimmunol. 153 (2004) 40-49
138. Li X.Y., and Niederkorn J.Y. Immune privilege in the anterior chamber of the eye is not extended to intraocular Listeria monocytogenes. Ocul. Immunol. Inflamm. 5 (1997) 245-257
139. Liao M.J., Zhang X.X., et al. No requirement for V(D)J recombination in p53-deficient thymic lymphoma. Mol. Cell. Biol. 18 (1998) 3495-3501
140. Likhvantseva V.G., Slepova O.S., et al. [Interferon status of patients with uveal melanoma]. Vestn. Oftalmol. 115 (1999) 35-37
141. Lin E.Y., and Pollard J.W. Role of infiltrated leucocytes in tumour growth and spread. Br. J. Cancer 90 (2004) 2053-2058
142. Ljunggren H.G., and Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol. Today 11 (1990) 237-244
143. Luyten G.P., van der Spek C.W., et al. Expression of MAGE, gp100 and tyrosinase genes in uveal melanoma cell lines. Melanoma Res. 8 (1998) 11-16
144. Ma D., Alizadeh H., et al. Rejection of intraocular tumors from transgenic mice by tumor-infiltrating lymphocytes. Curr. Eye Res. 13 (1994) 361-369
145. Ma D., Comerford S., et al. Capacity of simian virus 40 T antigen to induce self-tolerance but not immunological privilege in the anterior chamber of the eye. Transplantation 57 (1994) 718-725
146. Ma D., Luyten G.P., et al. Relationship between natural killer cell susceptibility and metastasis of human uveal melanoma cells in a murine model. Invest. Ophthalmol. Vis. Sci. 36 (1995) 435-441
147. Ma D., and Niederkorn J.Y. Transforming growth factor-beta down-regulates major histocompatibility complex class I antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-mediated cytolysis. Immunology 86 (1995) 263-269
148. Mahoney M.C., Burnett W.S., et al. The epidemiology of ophthalmic malignancies in New York State. Ophthalmology 97 (1990) 1143-1147
149. Makitie T., Summanen P., et al. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest. Ophthalmol. Vis. Sci. 42 (2001) 1414-1421
150. Malina H.Z., and Martin X.D. Indoleamine 2,3-dioxygenase activity in the aqueous humor, iris/ciliary body, and retina of the bovine eye. Graefes. Arch. Clin. Exp. Ophthalmol. 231 (1993) 482-486
151. Malina H.Z., and Martin X.D. Indoleamine 2,3-dioxygenase: antioxidant enzyme in the human eye. Graefes. Arch. Clin. Exp. Ophthalmol. 234 (1996) 457-462
152. Mantovani A., Allavena P., et al. Cancer-related inflammation. Nature 454 (2008) 436-444
153. Marincola F.M., Jaffee E.M., et al. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74 (2000) 181-273
154. Matsui K., Sawa T., et al. Relapse of stage I small cell lung cancer ten or more years after the start of treatment. Jpn. J. Clin. Oncol. 36 (2006) 457-461
155. McCarthy J.M., Rootman J., et al. Conjunctival and uveal melanoma in the dysplastic nevus syndrome. Surv. Ophthalmol. 37 (1993) 377-386
156. McKenna, K.C., Beatty, K.M., et al., in press. Activated CD11b+ CD15+ granulocytes increase in blood of uveal melanoma patients. Invest. Ophthalmol. Vis. Sci.
157. McKenna K.C., and Kapp J.A. Accumulation of immunosuppressive CD11b+ myeloid cells correlates with the failure to prevent tumor growth in the anterior chamber of the eye. J. Immunol. 177 (2006) 1599-1608
158. Medawar P.B. Immunity to homologous grafted skin. III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br. J. Exp. Pathol. 29 (1948) 58-69
159. Meecham W.J., Char D.H., et al. Infiltrating lymphocytes and antigen expression in uveal melanoma. Ophthal. Res. 24 (1992) 20-26
160. Mellor A.L., Keskin D.B., et al. Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J. Immunol. 168 (2002) 3771-3776
161. Meng S., Tripathy D., et al. Circulating tumor cells in patients with breast cancer dormancy. Clin. Cancer Res. 10 (2004) 8152-8162
162. Mizuno K., Altman N.F., et al. Histopathologic analysis of experimental autoimmune uveitis attenuated by intracameral injection of S-antigen. Curr. Eye Res. 8 (1989) 113-121
163. Mizuno K., Clark A.F., et al. Induction of anterior chamber associated immune deviation in rats receiving intracameral injections of retinal S antigen. Curr. Eye Res. 7 (1988) 627-632
164. Mulcahy K.A., Rimoldi D., et al. Infrequent expression of the MAGE gene family in uveal melanomas. Int. J. Cancer 66 (1996) 738-742
165. Munn D.H., Shafizadeh E., et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 189 (1999) 1363-1372
166. Munn D.H., Zhou M., et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281 (1998) 1191-1193
167. Nacht M., and Jacks T. V(D)J recombination is not required for the development of lymphoma in p53-deficient mice. Cell Growth Differ 9 (1998) 131-138
168. Namba K., Kitaichi N., et al. Induction of regulatory T cells by the immunomodulating cytokines alpha-melanocyte-stimulating hormone and transforming growth factor-beta2. J. Leukoc. Biol. 72 (2002) 946-952
169. Natali P.G., Bigotti A., et al. Analysis of the antigenic profile of uveal melanoma lesions with anti-cutaneous melanoma-associated antigen and anti-HLA monoclonal antibodies. Cancer Res. 49 (1989) 1269-1274
170. Niederkorn J., Streilein J.W., et al. Deviant immune responses to allogeneic tumors injected intracamerally and subcutaneously in mice. Invest. Ophthalmol. Vis. Sci. 20 (1981) 355-363
171. Niederkorn J.Y. The immunopathology of intraocular tumour rejection. Eye 5 (1991) 186-192
172. Niederkorn J.Y. Immunopathogenesis of intraocular tumors. Prog. Ret. Eye Res. 14 (1995) 505-526
173. Niederkorn J.Y. Immunoregulation of intraocular tumours. Eye 11 (1997) 249-254
174. Niederkorn J.Y. Natural killer cells and uveal melanoma. In: Zierhut M., Jager M.J., and Ksander B. (Eds). Immunology of Intraocular Tumors (2002), Swets and Zeitlinger, Lisse 73-82
175. Niederkorn J.Y. Anterior chamber-associated immune deviation and its impact on corneal allograft survival. Curr. Opin. Organ Transplant. 11 (2006) 360-365
176. Niederkorn J.Y. See no evil, hear no evil, do no evil: the lessons of immune privilege. Nat. Immunol. 7 (2006) 354-359
177. Niederkorn J.Y. The induction of anterior chamber-associated immune deviation. Chem. Immunol. Allergy 92 (2007) 27-35
178. Niederkorn J.Y., Chiang E.Y., et al. Expression of a nonclassical MHC class Ib molecule in the eye. Transplantation 68 (1999) 1790-1799
179. Niederkorn J.Y., and Knisely T.L. Immunological analysis of a destructive pattern of intraocular tumor resolution. Curr. Eye Res. 7 (1988) 515-526
180. Niederkorn J.Y., and Mellon J. Anterior chamber-associated immune deviation promotes corneal allograft survival. Invest. Ophthalmol. Vis. Sci. 37 (1996) 2700-2707
181. Niederkorn J.Y., and Meunier P.C. Spontaneous immune rejection of intraocular tumors in mice. Invest. Ophthalmol. Vis. Sci. 26 (1985) 877-884
182. Niederkorn J.Y., and Wang S. Immunology of intraocular tumors. Ocul. Immunol. Inflamm. 13 (2005) 105-110
183. Nishida T., and Taylor A.W. Specific aqueous humor factors induce activation of regulatory T cells. Invest. Ophthalmol. Vis. Sci. 40 (1999) 2268-2274
184. Nishimura H., and Honjo T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol. 22 (2001) 265-268
185. Nitta T., Oksenberg J.R., et al. Predominant expression of T cell receptor V alpha 7 in tumor-infiltrating lymphocytes of uveal melanoma. Science 249 (1990) 672-674
186. Okazaki T., and Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 19 (2007) 813-824
187. Old L.J., and Boyse E.A. Specific antigens of tumors and leukemias of experimental animals. Med. Clin. North Am. 50 (1966) 901-912
188. Ostrand-Rosenberg S., and Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 182 (2009) 4499-4506
189. Penn I. Malignant melanoma in organ allograft recipients. Transplantation 61 (1996) 274-278
190. Prehn R.T. The immune reaction as a stimulator of tumor growth. Science 176 (1972) 170-171
191. Prehn R.T., and Lappe M.A. An immunostimulation theory of tumor development. Transplant. Rev. 7 (1971) 26-54
192. Raja S.M., Metkar S.S., et al. Cytotoxic granule-mediated apoptosis: unraveling the complex mechanism. Curr. Opin. Immunol. 15 (2003) 528-532
193. Reese A.B. Precancerous and cancerous melanosis. Am. J. Ophthalmol. 61 (1966) 1272-1277
194. Reiman J.M., Kmieciak M., et al. Tumor immunoediting and immunosculpting pathways to cancer progression. Semin. Cancer Biol. 17 (2007) 275-287
195. Repp A.C., Mayhew E.S., et al. Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells. J. Immunol. 165 (2000) 710-715
196. Roberts S.J., Ng B.Y., et al. Characterizing tumor-promoting T cells in chemically induced cutaneous carcinogenesis. Proc. Natl. Acad. Sci. USA 104 (2007) 6770-6775
197. Rook A.H., Kehrl J.H., et al. Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J. Immunol. 136 (1986) 3916-3920
198. Rooney I.A., Oglesby T.J., et al. Complement in human reproduction: activation and control. Immunol. Res. 12 (1993) 276-294
199. Rouas-Freiss N., Goncalves R.M., et al. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc. Natl. Acad. Sci. USA 94 (1997) 11520-11525
200. Ruiter D.J., Bergman W., et al. Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens. Cancer Res. 44 (1984) 3930-3935
201. Ruiter D.J., Bhan A.K., et al. Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferations and malignant melanoma. J. Immunol. 129 (1982) 2808-2815
202. Ruiter D.J., Mattijssen V., et al. MHC antigens in human melanomas. Semin. Cancer Biol. 2 (1991) 35-45
203. Russell P., Gregerson D.S., et al. Characteristics of a retrovirus associated with a hamster melanoma. J. Gen. Virol. 43 (1979) 317-326
204. Ryu Y.H., and Kim J.C. Expression of indoleamine 2,3-dioxygenase in human corneal cells as a local immunosuppressive factor. Invest. Ophthalmol. Vis. Sci. 48 (2007) 4148-4152
205. Sagalowsky A.I., and Molberg K. Solitary metastasis of renal cell carcinoma to the contralateral adrenal gland 22 years after nephrectomy. Urology 54 (1999) 162
206. Saunders P.A., Hendrycks V.R., et al. PD-L2:PD-1 involvement in T cell proliferation, cytokine production, and integrin-mediated adhesion. Eur. J. Immunol. 35 (2005) 3561-3569
207. Schneider P., Holler N., et al. Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187 (1998) 1205-1213
208. Schurmans L.R., den Boer A.T., et al. Successful immunotherapy of an intraocular tumor in mice. Cancer Res. 59 (1999) 5250-5254
209. Schurmans L.R., Diehl L., et al. Rejection of intraocular tumors by CD4(+) T cells without induction of phthisis. J. Immunol. 167 (2001) 5832-5837
210. Shacter E., and Weitzman S.A. Chronic inflammation and cancer. Oncology (Williston Park) 16 (2002) 217-226 229; discussion 230-212
211. Shankaran V., Ikeda H., et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410 (2001) 1107-1111
212. She S.C., Steahly L.P., et al. Intracameral injection of allogeneic lymphocytes enhances corneal graft survival. Invest. Ophthalmol. Vis. Sci. 31 (1990) 1950-1956
213. Shen L., Jin Y., et al. The function of donor versus recipient programmed death-ligand 1 in corneal allograft survival. J. Immunol. 179 (2007) 3672-3679
214. Sherman S.H., Green K., et al. The fate of anterior chamber flurescein in the monkey eye. 1. The anterior chamber outflow pathways. Exp. Eye Res. 27 (1978) 159-173
215. Singh A.D., and Topham A. Survival rates with uveal melanoma in the United States: 1973-1997. Ophthalmology 110 (2003) 962-965
216. Smyth M.J., Dunn G.P., et al. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol. 90 (2006) 1-50
217. Smyth M.J., Thia K.Y., et al. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J. Exp. Med. 192 (2000) 755-760
218. Sohn J.H., Kaplan H.J., et al. Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins. Invest. Ophthalmol. Vis. Sci. 41 (2000) 3492-3502
219. Sohn J.H., Kaplan H.J., et al. Complement regulatory activity of normal human intraocular fluid is mediated by MCP, DAF, and CD59. Invest. Ophthalmol. Vis. Sci. 41 (2000) 4195-4202
220. Sonoda K.H., Taniguchi M., et al. Long-term survival of corneal allografts is dependent on intact CD1d-reactive NKT cells. J. Immunol. 168 (2002) 2028-2034
221. Sonoda Y., and Streilein J.W. Impaired cell-mediated immunity in mice bearing healthy orthotopic corneal allografts. J. Immunol. 150 (1993) 1727-1734
222. Staibano S., Mascolo M., et al. Tumor infiltrating lymphocytes in uveal melanoma: a link with clinical behavior?. Int. J. Immunopathol. Pharmacol. 19 (2006) 171-179
223. Streilein J.W. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat. Rev. Immunol. 3 (2003) 879-889
224. Streilein J.W., and Niederkorn J.Y. Induction of anterior chamber-associated immune deviation requires an intact, functional spleen. J. Exp. Med. 153 (1981) 1058-1067
225. Stuart P.M., Griffith T.S., et al. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J. Clin. Invest. 99 (1997) 396-402
226. Stutman O. Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science 183 (1974) 534-536
227. Stutman O. Immunodepression and malignancy. Adv. Cancer Res. 22 (1975) 261-422
228. Sugita S., Usui Y., et al. Human corneal endothelial cells expressing programmed death-ligand 1 (PD-L1) suppress PD-1 + T helper 1 cells by a contact-dependent mechanism. Invest. Ophthalmol. Vis. Sci. 50 (2009) 263-272
229. Swann J.B., and Smyth M.J. Immune surveillance of tumors. J. Clin. Invest. 117 (2007) 1137-1146
230. Takikawa O., Habara-Ohkubo A., et al. Induction of indoleamine 2,3-dioxygenase in tumor cells transplanted into allogeneic mouse: interferon-gamma is the inducer. Adv. Exp. Med. Biol. 294 (1991) 437-444
231. Takikawa O., Littlejohn T., et al. Regulation of indoleamine 2,3-dioxygenase, the first enzyme in UV filter biosynthesis in the human lens. Relevance for senile nuclear cataract. Adv. Exp. Med. Biol. 467 (1999) 241-245
232. Taniguchi K., Petersson M., et al. Interferon gamma induces lung colonization by intravenously inoculated B16 melanoma cells in parallel with enhanced expression of class I major histocompatibility complex antigens. Proc. Natl. Acad. Sci. USA 84 (1987) 3405-3409
233. Taylor A., and Namba K. In vitro induction of CD25 + CD4+ regulatory T cells by the neuropeptide alpha-melanocyte stimulating hormone (alpha-MSH). Immunol. Cell. Biol. 79 (2001) 358-367
234. Taylor A.W. Ocular immunosuppressive microenvironment. Chem. Immunol. 92 (2007) 71-85
235. Taylor A.W., and Yee D.G. Somatostatin is an immunosuppressive factor in aqueous humor. Invest. Ophthalmol. Vis. Sci. 44 (2003) 2644-2649
236. Teng M.W., Swann J.B., et al. Immune-mediated dormancy: an equilibrium with cancer. J. Leukoc. Biol. 84 (2008) 988-993
237. Terness P., Bauer T.M., et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med. 196 (2002) 447-457
238. Thomas L. Reactions to homologous tissue antigens in relation to hypersensitivity. In: Lawrence H.S. (Ed). Cellular and Humoral Aspects of the Hypersensitive States (1959), Hoebers-Harper, New York 529-532
239. Uyttenhove C., Pilotte L., et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9 (2003) 1269-1274
240. van Dooremaal J.C. Die Entwicklung der in fremden Grund versetzten lebenden Geweba. Albrecht von Graefes Arch. Ophthalmol. 19 (1873) 358-373
241. van Duinen S.G., Ruiter D.J., et al. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res. 48 (1988) 1019-1025
242. Verbik D.J., Murray T.G., et al. Melanomas that develop within the eye inhibit lymphocyte proliferation. Int. J. Cancer 73 (1997) 470-478
243. Vetter C.S., Lieb W., et al. Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma. Br. J. Cancer 91 (2004) 1495-1499
244. Vijayasaradhi S., and Houghton A.N. Melanoma and melanocytes: pigmentation, tumor progression, and the immune response to cancer. Adv. Pharmacol. 32 (1995) 343-374
245. Wang S., Boonman Z.F., et al. Role of TRAIL and IFN-gamma in CD4 + T cell-dependent tumor rejection in the anterior chamber of the eye. J. Immunol. 171 (2003) 2789-2796
246. Wang Y., Goldschneider I., et al. Blood mononuclear cells induce regulatory NK T thymocytes in anterior chamber-associated immune deviation. J. Leukoc. Biol. 69 (2001) 741-746
247. Weinlich G., Murr C., et al. Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients. Dermatology 214 (2007) 8-14
248. Whittum J.A., Niederkorn J.Y., et al. Intracameral inoculation of herpes simplex virus type I induces anterior chamber-associated immune deviation. Curr. Eye Res. 2 (1982) 691-697
249. Wilbanks G.A., Mammolenti M., et al. Studies on the induction of anterior chamber-associated immune deviation (ACAID). III. Induction of ACAID depends upon intraocular transforming growth factor-beta. Eur. J. Immunol. 22 (1992) 165-173
250. Wilbanks G.A., and Streilein J.W. Studies on the induction of anterior chamber-associated immune deviation (ACAID). 1. Evidence that an antigen-specific, ACAID-inducing, cell-associated signal exists in the peripheral blood. J. Immunol. 146 (1991) 2610-2617
251. Wilbanks G.A., and Streilein J.W. Fluids from immune privileged sites endow macrophages with the capacity to induce antigen-specific immune deviation via a mechanism involving transforming growth factor-beta. Eur. J. Immunol. 22 (1992) 1031-1036
252. Xu C., Mao D., et al. A critical role for murine complement regulator crry in fetomaternal tolerance. Science 287 (2000) 498-501
253. Yamagami S., Kawashima H., et al. Role of Fas-Fas ligand interactions in the immunorejection of allogeneic mouse corneal transplants. Transplantation 64 (1997) 1107-1111
254. Yang W., Chen P.W., et al. PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro. Invest. Ophthalmol. Vis. Sci. 49 (2008) 2518-2525
255. Yang W., Li H., et al. PD-L1 expression on human ocular cells and its possible role in regulating immune-mediated ocular inflammation. Invest. Ophthalmol. Vis. Sci. 50 (2009) 273-280
256. Yoshida M., Kezuka T., et al. Participation of pigment epithelium of iris and ciliary body in ocular immune privilege. 2. Generation of TGF-beta-producing regulatory T cells. Invest. Ophthalmol. Vis. Sci. 41 (2000) 3862-3870
257. Yoshida M., Takeuchi M., et al. Participation of pigment epithelium of iris and ciliary body in ocular immune privilege. 1. Inhibition of T-cell activation in vitro by direct cell-to-cell contact. Invest. Ophthalmol. Vis. Sci. 41 (2000) 811-821
258. Zamiri P., Masli S., et al. Thrombospondin plays a vital role in the immune privilege of the eye. Invest. Ophthalmol. Vis. Sci. 46 (2005) 908-919
259. Zea A.H., Rodriguez P.C., et al. l-Arginine modulates CD3zeta expression and T cell function in activated human T lymphocytes. Cell. Immunol. 232 (2004) 21-31
260. Zeiss C.J., Johnson E.M., et al. Feline intraocular tumors may arise from transformation of lens epithelium. Vet. Pathol. 40 (2003) 355-362
261. Zirm E. Eine erfolgreiche totale Keratoplastik. Albrecht von Graefes. Arch. Ophthalmol. 64 (1906) 580-593